Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia

被引：30
|
作者：
Melenovsky, V
Wichterle, D
Simek, J
Malik, J
Haas, T
Ceska, R
Malik, M
机构：
[1] Charles Univ Prague, Dept Internal Med 3, Sch Med 1, Prague, Czech Republic
[2] Johns Hopkins Med Inst, Div Cardiol, Dept Med, Baltimore, MD 21205 USA
[3] St George Hosp, Sch Med, Dept Cardiol Sci, London, England
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2003年 / 92卷 / 03期
关键词：
D O I：
10.1016/S0002-9149(03)00643-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This randomized open-label trial investigated whether autonomic cardiovascular control is altered in middle-aged men with combined hyperlipidemia and whether such alterations are affected by short-term, lipid-lowering therapy with atorvastatin and/or fenofibrate. Compared with normolipidemic subjects, untreated subjects with combined hyperlipidemia had several abnormalities of autonomic tone, indicating increased sympathetic tone and decreased baroreflex sensitivity. The alterations in autonomic cardiovascular control were partially reversible by each of the lipid-lowering drugs. (C) 2003 by Excerpta Medica, Inc.
引用
收藏
页码：337 / 341
页数：5
相关论文
共 50 条
  • [31] Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia
    Huang, Congwu
    Cen, Chuan
    Wang, ChengXu
    Zhan, Haiyong
    Ding, Xin
    LIPIDS IN HEALTH AND DISEASE, 2014, 13
  • [32] Comparative metabolic effects of fenofibrate and atorvastatin in patients with combined hyperlipiderma
    Koh, KK
    Han, SH
    Quon, MJ
    Kang, WC
    Shin, MS
    Choi, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 396A - 396A
  • [33] Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: Reduction during atorvastatin and fenofibrate therapy
    Arca, Marcello
    Natoli, Silvia
    Micheletta, Fausta
    Riggi, Sara
    Di Angelantonio, Emanuele
    Montali, Anna
    Antonini, Teresa Maria
    Antonini, Roberto
    Diczfalusy, Ulf
    Iuliano, Luigi
    FREE RADICAL BIOLOGY AND MEDICINE, 2007, 42 (05) : 698 - 705
  • [34] Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome
    Watts, GF
    Barrett, PHR
    Ji, JY
    Serone, AP
    Chan, DC
    Croft, KD
    Loehrer, F
    Johnson, AG
    DIABETES, 2003, 52 (03) : 803 - 811
  • [35] Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia
    Giral, P
    Bruckert, E
    Jacob, N
    Chapman, MJ
    Foglietti, MJ
    Turpin, G
    ATHEROSCLEROSIS, 2001, 154 (02) : 421 - 427
  • [36] EFFECTS OF HYPOLIPIDEMIC DRUGS (ATORVASTATIN, FENOFIBRATE AND COMBINED TREATMENT) ON INSULIN RESISTANCE INDEX, ADIPOKINES AND INFLAMMATORY MARKERS IN DYSLIPIDEMIC SUBJECTS
    Buldak, L.
    Okopien, B.
    Krysiak, R.
    Labuzek, K.
    Dulawa-Buldak, A.
    ATHEROSCLEROSIS, 2014, 235 (02) : E189 - E189
  • [37] Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?
    Michael H Davidson
    Nature Clinical Practice Cardiovascular Medicine, 2006, 3 : 594 - 595
  • [38] Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial)
    Grundy, SM
    Vega, GL
    Yuan, Z
    Battisti, WP
    Brady, WE
    Palmisano, J
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (04): : 462 - 468
  • [39] Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?
    Davidson, Michael H.
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (11): : 594 - 595
  • [40] Fluvastatin vs fluvastatin plus fenofibrate in CHD patients and combined hyperlipidemia
    Widimsky, J
    Hulinsky, V
    Balazovjech, I
    Lanska, V
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 63 - 63
12345